Efavirenz
- Generic Name
- Efavirenz
- Brand Names
- Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C14H9ClF3NO2
- CAS Number
- 154598-52-4
- Unique Ingredient Identifier
- JE6H2O27P8
- Background
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
...
- Indication
For use in combination treatment of HIV infection (AIDS)
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Preventing Sexual Transmission of HIV With Anti-HIV Drugs
- First Posted Date
- 2003-12-17
- Last Posted Date
- 2021-11-05
- Target Recruit Count
- 3526
- Registration Number
- NCT00074581
- Locations
- 🇺🇸
Fenway Community Health Ctr. CRS, Boston, Massachusetts, United States
🇧🇼Gaborone CRS, Gaborone, Botswana
🇧🇷Hospital Geral de Nova Iguaçu CRS (HGNI CRS), Nova Iguacu, Rio De Janeiro, Brazil
A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy
- Conditions
- First Posted Date
- 2003-02-05
- Last Posted Date
- 2010-10-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 345
- Registration Number
- NCT00053638
- Locations
- 🇺🇸
GSK Investigational Site, Green Bay, Wisconsin, United States
Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV
- Conditions
- Interventions
Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients
- Conditions
- First Posted Date
- 2003-01-01
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 775
- Registration Number
- NCT00050895
- Locations
- 🇺🇸
IHV Baltimore Treatment CRS, Baltimore, Maryland, United States
🇺🇸UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Conditions
- Interventions
- Drug: darunavir/ritonavir dosage #1Drug: TAF w/cobicistatDrug: TAF w/cobicistat or ritonavirDrug: tenofovir alafenamide fumarate (TAF)Drug: elvitegravir/cobicistatDrug: darunavir/cobicistatDrug: atazanavir/cobicistatDrug: lopinavir/ritonavir dosage #1Drug: atazanavir/ritonavir/tenofovir dosage #1Drug: lopinavir/ritonavir dosage #2Drug: indinavir/ritonavir dosage #1Drug: fosamprenavir/ritonavirDrug: atazanavir/ritonavir dosage #1Drug: didanosine delayed release (Videx® EC)Drug: emtricitabineDrug: nelfinavir dosage #1Drug: tipranavir/ritonavirDrug: etravirineDrug: darunavir/ritonavir dosage #4Drug: indinavir/ritonavir dosage #2Drug: rilpivirineDrug: ethambutolDrug: efavirenzDrug: raltegravirDrug: dolutegravirDrug: kanamycinDrug: nevirapineDrug: amprenavirDrug: abacavirDrug: tenofovirDrug: maravirocDrug: darunavir/ritonavir dosage #2Drug: lopinavir/ritonavir dosage #3Drug: lopinavir/ritonavir dosage #4Drug: tenofovir/atazanavir/ritonavir dosage #2Drug: atazanavir/ritonavir dosage #2Drug: nelfinavir dosage #2Drug: rifampicinDrug: amikacinDrug: darunavir/ritonavir dosage #3Drug: etonogestrel implantDrug: capreomycinDrug: ethinyl estradiolDrug: isoniazidDrug: moxifloxacinDrug: levoflaxacinDrug: pyrazinamideDrug: ofloxacinDrug: ethionamide/prothionamideDrug: terizidone/cycloserineDrug: para-aminosalicylic acid (PAS)Drug: high dose INHDrug: bedaquilineDrug: clofazamineDrug: delamanidDrug: linezolidDrug: pretomanid
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2022-07-22
- Target Recruit Count
- 1578
- Registration Number
- NCT00042289
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇿🇦Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa
🇺🇸Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States
Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART
- Conditions
- First Posted Date
- 2002-06-03
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Abbott
- Target Recruit Count
- 24
- Registration Number
- NCT00038532
- Locations
- 🇨🇦
Toronto General Hospital Division of The University Health Network, Toronto, Ontario, Canada
🇺🇸University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸Diversified Medical Practices, P.A., Houston, Texas, United States
Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients
- Conditions
- First Posted Date
- 2002-05-30
- Last Posted Date
- 2006-07-27
- Lead Sponsor
- Abbott
- Target Recruit Count
- 40
- Registration Number
- NCT00038220
- Locations
- 🇺🇸
Aaron Diamond AIDS Research Center - Rockefeller University, New York, New York, United States
Increasing HAART-Induced Immune Restoration With Cyclosporine
- Conditions
- First Posted Date
- 2002-02-22
- Last Posted Date
- 2015-03-09
- Target Recruit Count
- 40
- Registration Number
- NCT00031070
- Locations
- 🇺🇸
Univ of Texas, Southwestern Med Ctr of Dallas, Dallas, Texas, United States
🇺🇸Washington Univ (St. Louis), St. Louis, Missouri, United States
🇺🇸University of Pennsylvania, Philadelphia, Philadelphia, Pennsylvania, United States
Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care
- Conditions
- First Posted Date
- 2001-12-21
- Last Posted Date
- 2011-03-02
- Target Recruit Count
- 250
- Registration Number
- NCT00028327
- Locations
- 🇺🇸
Beth Israel Med Ctr, New York, New York, United States
🇺🇸Univ of California San Francisco, San Francisco, California, United States
🇺🇸Washington Univ School of Medicine, St Louis, Missouri, United States
TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz
- Conditions
- First Posted Date
- 2001-09-10
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 20
- Registration Number
- NCT00023413
- Locations
- 🇺🇸
Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.